REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets rare genetic mutation in advanced cancers
Disease control OngoingThis study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. The goal is to see if the drug can s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:10 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:09 UTC
-
Targeted drug shows promise for rare BRAF-driven cancers
Disease control OngoingThis study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF genetic changes (non-V600 mutations or fusions). The goal was to see if trametinib could shrink or stop cancer growth by blocking certain proteins. While the treatment may help contro…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:08 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed by surgery. The stud…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:08 UTC
-
Targeted drug shows promise for rare cancers with ROS1 mutation
Disease control OngoingThis study tested the drug crizotinib in 4 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called ROS1 translocation. The drug blocks a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or st…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:07 UTC
-
New drug targets Cancer's weak spot in 35-Patient trial
Disease control OngoingThis study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost a protein called PTEN. The drug blocks a growth signal that these cancer cells rely on. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial,…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:07 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:06 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control OngoingThis study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the treatment to see if it can shrin…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
Targeted drug sunitinib tested on rare cancers with cKIT mutation
Disease control OngoingThis study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that tell cancer cells to grow. The goal is to see if the drug can shrink or slow the cancer. About 10 adults with certain lymphom…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
Precision drug shows promise for rare genetic cancers
Disease control OngoingThis study tests a drug called larotrectinib in people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. About 35 adults with various solid tumors or lymphomas that haven't responded to …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New drug targets BRCA cancers in precision trial
Disease control OngoingThis study tests a drug called AZD1775 in people whose advanced cancers have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 35 adults with various advanced cancers a…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
Experimental combo aims to outsmart resistant cancers
Disease control OngoingThis study tests whether adding the experimental drug TRC102 to standard chemotherapy (cisplatin and pemetrexed) can shrink tumors or slow cancer growth in people with advanced solid tumors or mesothelioma that have not responded to prior treatments. About 30 adults will take par…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:03 UTC
-
Targeted pill shows promise for rare genetic cancer subtype
Disease control OngoingThis study tests a drug called crizotinib in people with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug blocks enzymes that help cancer cells grow and spread. About 20 participants will receive the treatment to see if their tumors shrin…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
New chemo wrap may sneak deeper into tumors
Disease control OngoingThis early-phase study tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is wrapped in a special polymer to help it reach deeper into cancer cells while spari…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
New hope for kids with relapsed cancers: experimental drug elimusertib under study
Disease control OngoingThis study tests an experimental drug called elimusertib in children and young adults whose solid tumors have returned or not responded to standard treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking enzymes that cancer cells need to g…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
New hope for rare cancers: drug targets NF2 mutation
Disease control OngoingThis study is for people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NF2 mutation. The drug defactinib works by blocking a protein (FAK) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New combo targets Taxane-Resistant cancers in phase 2 trial
Disease control OngoingThis study tests whether adding nilotinib to paclitaxel can help control solid tumors that have continued to grow after prior taxane therapy. About 40 adults with advanced or worsening cancers will receive the combination. The goal is to see if the drugs work together to slow tum…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for Hard-to-Treat cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called palbociclib in 43 patients with advanced or hard-to-treat cancers that have specific changes in the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to grow. The main goal is to see if the drug can shrink tumors or stop …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug targets Hard-to-Treat cancers with PTEN mutation
Disease control OngoingThis study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a protein that helps cancer cells grow, aiming to shrink tumors or stop them from spreading. The main goal is to see h…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial studies the safety and best dose of two drugs, riluzole and sorafenib, given together to adults with advanced solid tumors or melanoma that has spread and is no longer responding to standard treatments. The goal is to find a dose that limits side effects wh…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Targeted drug crizotinib tested against hard-to-treat MET-amplified cancers
Disease control OngoingThis study tests the drug crizotinib in people whose advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal is …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that have specific genetic mutations. The goal was to find the best dose and check for side effects. The approach aims to shrink or stabilize tumor…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for Hard-to-Treat cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called afatinib in 19 adults with advanced cancers (like lymphoma or solid tumors) that have a specific EGFR gene mutation and have stopped responding to standard treatments. Afatinib works by blocking the faulty EGFR protein that helps cancer cells grow. …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Targeted drug shows promise for NF1-Mutated tumors
Disease control OngoingThis study tests a drug called trametinib in 50 adults with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. Par…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study is for people with advanced solid tumors that have specific gene changes (KRAS or NRAS mutations) and have not responded to standard treatments. It tests two drugs: trametinib, which blocks a protein that helps cancer grow, and navitoclax, which blocks proteins that ke…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain brain, kidney, and soft tissue tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
Targeted pill shows promise for rare genetic cancers
Disease control OngoingThis study tests a daily pill called osimertinib in people with advanced cancers that have certain EGFR gene changes. The drug blocks a faulty protein that helps tumors grow. Researchers want to see if it can shrink tumors or slow the disease in 19 patients with various cancer ty…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New hope for rare cancers: targeted pill shrinks tumors in early trial
Disease control OngoingThis study tests a drug called binimetinib in 53 adults with advanced cancers that have a specific genetic change (NRAS mutation). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial f…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New drug targets genetic flaw in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. The goal is to see if it can shrink tumors or stop them from getting worse for at least 6 months. About 35 …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:51 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug targets rare BRAF mutations in advanced cancers
Disease control OngoingThis study tests a drug called ulixertinib in people with advanced cancers that have certain changes in the BRAF gene (mutations or fusions). The drug works by blocking signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that h…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for Hard-to-Treat cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called taselisib in people whose cancer has a specific genetic change (PIK3CA mutation) but not certain other changes. The drug aims to block a protein that helps cancer grow. About 70 adults with advanced solid tumors or lymphomas that haven't responded t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Targeted drug combo shows promise for rare BRAF-Mutated cancers
Disease control OngoingThis study tests two targeted drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific BRAF gene mutation (V600E or V600K). The goal is to see if the combination can shrink tumors or stop them from growing. About 44 adults with various cancer types (…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug cocktail aims to starve and shrink Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a combination of two drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could block tumor growth by cutting off blood…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo therapy targets tough cancers with gene mutations
Disease control OngoingThis early-phase study tests the safety and best dose of the drug neratinib combined with everolimus, palbociclib, or trametinib in people with advanced solid tumors that have not responded to standard treatments. Participants must have certain gene changes (EGFR, HER2, HER3, HER…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Targeted drug shows promise for rare mutation-driven cancers
Disease control OngoingThis study tests the drug trametinib in people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from getting worse. Only 4 patients too…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug targets AKT mutations in advanced cancers
Disease control OngoingThis study tests a drug called ipatasertib in 35 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the tumors shrin…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for Hard-to-Treat cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called palbociclib in 40 adults with advanced cancers that have extra copies of the CCND1, 2, or 3 genes. The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse.
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Targeted drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the results help researchers unde…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy aims to shrink advanced cancers
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Targeted drug shows promise for HER2-Mutated cancers
Disease control OngoingThis study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Targeted therapy shows promise for rare HER2-Positive cancers
Disease control OngoingThis study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New combo targets Cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs (avelumab and M6620) in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see how well the drugs work together t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called copanlisib in people whose advanced cancers have a specific genetic change (PIK3CA mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with var…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
New drug targets AKT mutations in Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Childhood cancer immunotherapy trial pulled before starting
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for hard-to-treat cancers with rare gene mutations
Disease control OngoingThis study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Promising combo fails to shrink IDH-Mutant tumors in early trial
Disease control OngoingThis study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors that have an IDH mutation, including a type of bile duct cancer. The goal was to see if the combination could shrink or stop tumor growth. Unfortunately, no patients had their tumors s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Expert tumor board aims to unlock genetic secrets for advanced cancer patients
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will be involved, and their doctors will either use the…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC
-
New drug DS-8201a shows promise in targeting Hard-to-Treat cancers
Knowledge-focused OngoingThis early-phase trial looks at how DS-8201a works in patients with advanced HER2-positive solid tumors that have spread or cannot be removed. The drug targets a protein on cancer cells to damage their DNA and kill them. Researchers will compare tumor samples taken before and aft…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 03:54 UTC
-
Gene-Guided hope: pediatric MATCH trial aims to outsmart tough childhood cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC